Lifeward Ltd.

06/16/2025 | Press release | Distributed by Public on 06/16/2025 07:27

Proxy Statement, Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer.

Director Appointment

On June 15, 2025, the Board of Directors (the "Board") of Lifeward Ltd. (the "Company") increased the size of the Board from seven directors to eight directors and appointed Mark Grant as a Class II director, effective June 15, 2025. Mr. Grant will hold office until the 2025 Annual General Meeting of Shareholders (the "Annual Meeting"), scheduled to be held on August 1, 2025, and until his successor has been duly qualified or his earlier resignation or removal. As previously disclosed, Mr. Grant was appointed as the Company's President and Co-Chief Executive Officer, effective as of June 2, 2025.

There are no arrangements or understandings between Mr. Grant and any other person pursuant to which Mr. Grant was appointed as a director. There are no transactions involving Mr. Grant requiring disclosure under Item 404(a) of Regulation S-K. As an employee director, Mr. Grant will not receive any compensation for his service as a member of the Board.

Director Resignation

On June 15, 2025, Larry Jasinski, a member of the Board and the Company's Co-Chief Executive Officer, notified the Board of his decision to resign as a member of the Board, effective as of June 30, 2025. Mr. Jasinski's decision to resign was not the result of any disagreement with the Company on any matters relating to the Company's operations, policies or practices. As previously disclosed, Mr. Jasinski will continue to serve as Co-Chief Executive Officer until June 30, 2025, after which he will serve in an advisory capacity on an as-needed basis through the end of 2025.

Item 5.08 Shareholder Director Nominations.
The Board has set the date for the Annual Meeting as August 1, 2025. Because the Annual Meeting will be held more than 30 days from the anniversary date of the Company's 2024 annual general meeting of shareholders, shareholders of the Company who wish to have a proposal considered for inclusion in the Company's proxy materials for the Annual Meeting pursuant to Rule 14a-8 of the Securities and Exchange Act of 1934, as amended, must ensure that such proposal is received by the Company's Chief Financial Officer at the Company's principal executive offices located at 200 Donald Lynch Blvd., Marlborough, Massachusetts, U.S.A., on or before June 23, 2025, including any notice on Schedule 14N, which the Company has determined is a reasonable time before it expects to begin to print and send its proxy materials. All shareholder proposals and nominations must comply with the rules and regulations promulgated by the Securities and Exchange Commission and under the Israel Companies Law 5759-1999, and with the Company's Articles of Association, as applicable.

Lifeward Ltd. published this content on June 16, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 16, 2025 at 13:27 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io